XML 108 R38.htm IDEA: XBRL DOCUMENT v2.4.1.9
Business Segments (Tables)
 12 Months Ended
Dec. 31, 2014
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment

 
Year ended December 31, 2014
 
Apex
 
Oxford
 
Life Sciences Europe
 
Corporate
 
Total
Revenues
$
1,190,052

 
$
493,320

 
$
41,369

 
$
—

 
$
1,724,741

Gross Profit
335,322

 
208,607

 
13,506

 
—

 
557,435

Operating income
$
121,334

 
$
66,315

 
$
3,878

 
$
(53,745
)
 
137,782

Amortization
16,356

 
5,491

 
274

 
9

 
22,130


 
Year ended December 31, 2013
 
Apex
 
Oxford
 
Life Sciences Europe
 
Corporate
 
Total
Revenues
$
1,059,993

 
$
423,670

 
$
39,438

 
$
—

 
$
1,523,101

Gross Profit
294,611

 
147,348

 
12,916

 
—

 
454,875

Operating income
98,588

 
60,544

 
5,574

 
(48,119
)
 
116,587

Amortization
19,524

 
965

 
364

 
90

 
20,943

 
Year ended December 31, 2012
 
Apex

 
Oxford

 
Life Sciences Europe
 
Corporate
 
Total
Revenues
$
617,844

 
$
375,196

 
$
38,895

 
$
—

 
$
1,031,935

Gross Profit
174,968

 
132,034

 
14,252

 
—

 
321,254

Operating income
57,191

 
57,703

 
4,481

 
(46,362
)
 
73,013

Amortization
15,665

 
437

 
654

 
291

 
17,047
Disclosure on Geographic Areas, Description of Revenue from External Customers
The Company operates internationally, with operations in the United States, Europe, Canada, Australia, and New Zealand. The following table represents revenues by geographic location (in thousands):
 
 
Year Ended December 31,
 
 
2014
 
2013
 
2012
Revenues:
 
 
 
 
 
 
Domestic
 
$
1,643,598

 
$
1,446,805

 
$
958,342

Foreign
 
81,143

 
76,296

 
73,593

 
 
$
1,724,741

 
$
1,523,101

 
$
1,031,935
Schedule of Revenue by Geographical Areas
Business Segments
 
The Company has three reportable segments: Apex, Oxford, and Life Sciences Europe.

During the quarter ended March 31, 2014, the Company realigned its former Life Sciences Segment resulting in Lab Support U.S. now being included in the Apex Segment; Valesta U.S. now being included in the Oxford Segment; and the Life Sciences Europe Segment includes Lab Support Europe and Valesta Europe.

On February 1, 2015 the Company sold the Physician Segment. During 2014 the Company discontinued the operations of its European retained search unit, formerly included in the Life Sciences Europe Segment. During 2013, the Company sold its Nurse Travel and Allied Healthcare division (see "Note 5. Discontinued Operations" for further information). The realignment and divestitures resulted in changes to the internal reporting package reviewed by the Chief Operating Decision Maker ("CODM"), and the Healthcare Segment no longer exists. Health Information Management, formerly included in the Healthcare Segment, is included in the Oxford Segment and unallocated corporate expenses are separately disclosed in order to align with the revised internal reporting package reviewed by the CODM. All prior periods have been retrospectively restated to conform to the current presentation.

The Apex Segment provides information technology and scientific staffing professionals for contract, contract-to-hire and permanent placement positions to Fortune 1000 and mid-market clients across the United States, and offers consulting services for other select project-based needs. Apex Segment provides staffing and services support for companies from all major industries, including financial services, business services, consumer and industrials, technology, healthcare, government services, and communications.

The Oxford Segment provides high-end contract and direct hire placement services of information technology and engineering professionals with expertise in specialized information technology, software and hardware engineering, and mechanical, electrical, validation and telecommunications engineering fields.
    
The Life Sciences Europe Segment provides services of laboratory and scientific professionals to the biotechnology, pharmaceutical, food and beverage, medical device, personal care, chemical and environmental industries. These contract staffing specialties include chemists, clinical research associates, clinical lab assistants, engineers, biologists, biochemists, microbiologists, molecular biologists, food scientists, regulatory affairs specialists, lab assistants and other skilled scientific professionals.

The Company’s management evaluates the performance of each segment primarily based on revenues, gross profit, and operating income. The information in the following table is derived directly from the segments’ internal financial reporting used for corporate management purposes. The Company's management does not evaluate, manage or measure performance of segments using asset information, and such information is not readily available. Accordingly, assets by reportable segment are not disclosed.

The following tables present revenues, gross profit, operating income and amortization by reportable segment (in thousands):

 
Year ended December 31, 2014
 
Apex
 
Oxford
 
Life Sciences Europe
 
Corporate
 
Total
Revenues
$
1,190,052

 
$
493,320

 
$
41,369

 
$
—

 
$
1,724,741

Gross Profit
335,322

 
208,607

 
13,506

 
—

 
557,435

Operating income
$
121,334

 
$
66,315

 
$
3,878

 
$
(53,745
)
 
137,782

Amortization
16,356

 
5,491

 
274

 
9

 
22,130


 
Year ended December 31, 2013
 
Apex
 
Oxford
 
Life Sciences Europe
 
Corporate
 
Total
Revenues
$
1,059,993

 
$
423,670

 
$
39,438

 
$
—

 
$
1,523,101

Gross Profit
294,611

 
147,348

 
12,916

 
—

 
454,875

Operating income
98,588

 
60,544

 
5,574

 
(48,119
)
 
116,587

Amortization
19,524

 
965

 
364

 
90

 
20,943

 
Year ended December 31, 2012
 
Apex

 
Oxford

 
Life Sciences Europe
 
Corporate
 
Total
Revenues
$
617,844

 
$
375,196

 
$
38,895

 
$
—

 
$
1,031,935

Gross Profit
174,968

 
132,034

 
14,252

 
—

 
321,254

Operating income
57,191

 
57,703

 
4,481

 
(46,362
)
 
73,013

Amortization
15,665

 
437

 
654

 
291

 
17,047

 
The Company operates internationally, with operations in the United States, Europe, Canada, Australia, and New Zealand. The following table represents revenues by geographic location (in thousands):
 
 
Year Ended December 31,
 
 
2014
 
2013
 
2012
Revenues:
 
 
 
 
 
 
Domestic
 
$
1,643,598

 
$
1,446,805

 
$
958,342

Foreign
 
81,143

 
76,296

 
73,593

 
 
$
1,724,741

 
$
1,523,101

 
$
1,031,935


 
The following table represents long-lived assets by geographic location (in thousands):
 
 
December 31,
 
 
2014
 
2013
 
2012
Long-lived Assets:
 
 
 
 
 
 
Domestic
 
$
49,837

 
$
42,341

 
$
38,099

Foreign
 
2,091

 
2,394

 
2,006

 
 
$
51,928

 
$
44,735

 
$
40,105
Long Lived Assets By Geographic Location Domestic And Foreign
The following table represents long-lived assets by geographic location (in thousands):
 
 
December 31,
 
 
2014
 
2013
 
2012
Long-lived Assets:
 
 
 
 
 
 
Domestic
 
$
49,837

 
$
42,341

 
$
38,099

Foreign
 
2,091

 
2,394

 
2,006

 
 
$
51,928

 
$
44,735

 
$
40,105